Sign In
Buy MYOV
$26.98
+0 (+0%)
At Close: Jun 08, 2023
Myovant Squares Off with AbbVie On Endometriosis Treatment
11:55am, Sunday, 26'th Apr 2020
With positive clinical trial results and a confirmatory study expected to report this quarter, investors should dig in.
Relugolix Combination Therapy May Be The Way To Cope With Endometriosis Symptoms
11:20am, Sunday, 26'th Apr 2020
Myovant Sciences has announced the first of two Phase 3 studies looking into therapy for women suffering from pain associated with endometriosis has had positive results.
Myovant Sciences Ltd (NYSE:MYOV) Major Shareholder Chemical Co. Ltd. Sumitomo Buys 50,000 Shares of Stock
11:08am, Saturday, 25'th Apr 2020
Myovant Sciences Ltd (NYSE:MYOV) major shareholder Chemical Co. Ltd. Sumitomo bought 50,000 shares of the stock in a transaction on Wednesday, April 22nd. The shares were bought at an average price of
Daily Insider Ratings Round Up 4/23/20
09:58pm, Friday, 24'th Apr 2020
Tables of the top insider purchases and sales filed with the SEC on 4/23/20, based on dollar value. Dollar values often do not equate with significance when it
Sumitovant Biopharma Reports Key Clinical and Regulatory Milestones by Myovant Sciences
02:58pm, Friday, 24'th Apr 2020
Sumitovant Biopharma Ltd. today announced that Myovant Sciences, one of five healthcare companies in the Sumitovant family of companies, achieved multiple milestones with its relugolix therapies for t
Daily Insider Ratings Round Up 4/21/20
03:57am, Thursday, 23'rd Apr 2020
Tables of the top insider purchases and sales filed with the SEC on 4/21/20, based on dollar value. Dollar values often do not equate with significance when it
Baird highlights biopharma with catalysts to come and 100% upside
07:37pm, Wednesday, 22'nd Apr 2020
News is free at Seeking Alpha.This post is a Notable Call. Notable Calls are a Premium feature.To access this and other Notable Calls, try a free trial to Seeking Alpha Premium.
Myovant Sciences to hold a pharmacetical update conference call MYOV
12:47pm, Wednesday, 22'nd Apr 2020
Myovant Sciences to hold a pharmacetical update conference call MYOV
BRIEF-Myovant Sciences Announces Positive Results From Phase 3 Spirit 2 Study
12:37pm, Wednesday, 22'nd Apr 2020
Myovant Sciences Ltd:
Myovant up 7% premarket on successful relugolix study
11:53am, Wednesday, 22'nd Apr 2020
Myovant Sciences (NYSE:MYOV) is up 7% premarket on light volume in reaction to positive results from a Phase 3 clinical trial, SPIRIT 2, evaluating once-daily relugolix combo therapy (relugolix 40 m
The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership
11:51am, Wednesday, 22'nd Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Ar
Myovant Eyes Relugolix Approval for Advanced Prostate Cancer
11:50am, Wednesday, 22'nd Apr 2020
Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix as a treatment for advanced prostate cancer.
Myovant Eyes Relugolix Approval for Advanced Prostate Cancer
11:50am, Wednesday, 22'nd Apr 2020
Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix as a treatment for advanced prostate cancer.
Myovant Sciences says co-primary endpoints met in Phase 3 SPIRIT 2 study MYOV
11:47am, Wednesday, 22'nd Apr 2020
Myovant Sciences says co-primary endpoints met in Phase 3 SPIRIT 2 study MYOV
Myovant Sciences (MYOV), a healthcare company focused on redefining care for women's health and prostate cancer, today announced that SPIRIT 2, the first of two Phase 3 studies of once-daily relugolix
